← Leaderboards
Dong-Er Zhang
Beth Israel Deaconess Medical Center
$30,254,830
Attributed
$31,925,153
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,925,153 · 18
By mechanism
R01$29,965,880 · 10
T32$994,451 · 1
P01$628,373 · 1
P30$196,529 · 1
R56$100,000 · 1
R13$29,420 · 2
Top collaborators
- Xiang-Dong Fu6 shared
- Andrew Clyde Kummel5 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- David L Van Vactor$25,144,586
- Bon Q Trinh$986,469
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularInsightCellsHematopoiesisGenesMalignant NeoplasmsHematopoieticSignal TransductionProteinsPlayMouse ModelLeukemiaRunx1 GeneBaseFundingGene ExpressionLead21)(Q22Q22)Chimeric ProteinsCell ProliferationPathway InteractionsMutationLeukemogenesis
Grant awards (106)
Molecular Mechanism of Leukemogenesis involving AML1-ETO$375,250
R01 · FY2025 · CA · contact PI
Molecular Mechanism of Leukemogenesis involving AML1-ETO$356,488
R01 · FY2024 · CA · contact PI
ISG15 and Protein ISGylation in Cancer$405,055
R01 · FY2023 · CA · contact PI
Molecular Mechanism of Leukemogenesis involving AML1-ETO$375,250
R01 · FY2023 · CA · contact PI
USP18 in Cancer Development$370,916
R01 · FY2023 · CA · contact PI
Cancer Biology and Signaling$31,940
P30 · FY2023 · CA · contact PI
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology$620,251
R01 · FY2022 · DK · contact PI
ISG15 and Protein ISGylation in Cancer$407,842
R01 · FY2022 · CA · contact PI
USP18 in Cancer Development$370,916
R01 · FY2022 · CA · contact PI
Molecular Mechanism of Leukemogenesis involving AML1-ETO$367,745
R01 · FY2022 · CA · contact PI
Cancer Biology and Signaling$30,105
P30 · FY2022 · CA · contact PI
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology$632,046
R01 · FY2021 · DK · contact PI
ISG15 and Protein ISGylation in Cancer$414,306
R01 · FY2021 · CA · contact PI
USP18 in Cancer Development$378,186
R01 · FY2021 · CA · contact PI
Molecular Mechanism of Leukemogenesis involving AML1-ETO$374,954
R01 · FY2021 · CA · contact PI
Cancer Researchers in Nanotechnology (CRIN)$205,769
T32 · FY2021 · CA · contact PI
Cancer Biology and Signaling$31,923
P30 · FY2021 · CA · contact PI
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology$641,790
R01 · FY2020 · DK · contact PI
ISG15 and Protein ISGylation in Cancer$412,014
R01 · FY2020 · CA · contact PI
USP18 in Cancer Development$377,288
R01 · FY2020 · CA · contact PI
Cancer Researchers in Nanotechnology (CRIN)$202,983
T32 · FY2020 · CA · contact PI
Cancer Biology and Signaling$70,739
P30 · FY2020 · CA · contact PI
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology$650,270
R01 · FY2019 · DK · contact PI
ISG15 and Protein ISGylation in Cancer$418,800
R01 · FY2019 · CA · contact PI
USP18 in Cancer Development$376,989
R01 · FY2019 · CA · contact PI
CSF2 receptor mediated actions in t(8;21) leukemia$330,714
R01 · FY2019 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$321,373
R01 · FY2019 · CA · contact PI
Cancer Researchers in Nanotechnology (CRIN)$200,261
T32 · FY2019 · CA · contact PI
Cancer Biology and Signaling$31,822
P30 · FY2019 · CA · contact PI
CSF2 receptor mediated actions in t(8;21) leukemia$342,403
R01 · FY2018 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$331,313
R01 · FY2018 · CA · contact PI
Cancer Researchers in Nanotechnology (CRIN)$197,605
T32 · FY2018 · CA · contact PI
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology$100,000
R56 · FY2018 · DK · contact PI
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology$424,003
R01 · FY2017 · DK · contact PI
CSF2 receptor mediated actions in t(8;21) leukemia$343,706
R01 · FY2017 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$331,313
R01 · FY2017 · CA · contact PI
ISG15 and protein ISGylation in Cancer$321,625
R01 · FY2017 · CA · contact PI
Cancer Researchers in Nanotechnology (CRIN)$187,833
T32 · FY2017 · CA · contact PI
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology$439,348
R01 · FY2016 · DK · contact PI
CSF2 receptor mediated actions in t(8;21) leukemia$344,868
R01 · FY2016 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$331,313
R01 · FY2016 · CA · contact PI
ISG15 and protein ISGylation in Cancer$321,625
R01 · FY2016 · CA · contact PI
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology$451,324
R01 · FY2015 · DK · contact PI
CSF2 receptor mediated actions in t(8;21) leukemia$345,907
R01 · FY2015 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$331,313
R01 · FY2015 · CA · contact PI
ISG15 and protein ISGylation in Cancer$321,625
R01 · FY2015 · CA · contact PI
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology$460,948
R01 · FY2014 · DK · contact PI
ISG15 and protein ISGylation in Cancer$311,976
R01 · FY2014 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$293,072
R01 · FY2014 · CA · contact PI
Synergestic roles of SRSF2 and RUNX1 in blood cell development and pathology$470,572
R01 · FY2013 · DK · contact PI
t(8;21) and SON in Blood Cell Proliferation and Differentiation$337,057
R01 · FY2013 · CA · contact PI
ISG15 and protein ISGylation in Cancer$321,625
R01 · FY2013 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$284,008
R01 · FY2013 · CA · contact PI
UBP43 in Hematopoiesis$382,388
R01 · FY2012 · HL · contact PI
t(8;21) and SON in Blood Cell Proliferation and Differentiation$358,571
R01 · FY2012 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$302,136
R01 · FY2012 · CA · contact PI
UBP43 in Hematopoiesis$386,250
R01 · FY2011 · HL · contact PI
t(8;21) and SON in Blood Cell Proliferation and Differentiation$358,571
R01 · FY2011 · CA · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$302,136
R01 · FY2011 · CA · contact PI
International RUNX Workshop$10,000
R13 · FY2011 · CA · contact PI
UBP43 in Hematopoiesis$386,250
R01 · FY2010 · HL · contact PI
t(8;21) and SON in Blood Cell Proliferation and Differentiation$354,471
R01 · FY2010 · CA · contact PI
Role of Ubiquitin Like Protein ISG15 Conjugation$320,588
R01 · FY2010 · GM · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$311,480
R01 · FY2010 · CA · contact PI
SEARCH AML1-ETO INTERACTING PROTEIN$2,425
P41 · FY2010 · RR · contact PI
UBP43 in Hematopoiesis$386,250
R01 · FY2009 · HL · contact PI
t(8;21) and SON in Blood Cell Proliferation and Differentiation$369,661
R01 · FY2009 · CA · contact PI
Role of Ubiquitin Like Protein ISG15 Conjugation$320,586
R01 · FY2009 · GM · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$41,715
R01 · FY2009 · CA · contact PI
FASEB Conference-Hematological Malignancies$9,710
R13 · FY2009 · CA · contact PI
UBP43 in Hematopoiesis$386,250
R01 · FY2008 · HL · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$302,407
R01 · FY2008 · CA · contact PI
Mechanism of Interferon Response and Resistance in CML$241,925
R01 · FY2008 · CA · contact PI
T(8;21) in Blood Cell Proliferation and Differentiation$63,345
R01 · FY2008 · CA · contact PI
SEARCH AML1-ETO INTERACTING PROTEIN$8,075
P41 · FY2008 · RR · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$364,846
R01 · FY2007 · CA · contact PI
Mechanism of Interferon Response and Resistance in CML$291,876
R01 · FY2007 · CA · contact PI
T(8;21) in Blood Cell Proliferation and Differentiation$289,338
R01 · FY2007 · CA · contact PI
UBP43 in Hematopoiesis$270,257
R01 · FY2007 · CA · contact PI
UBP43 in Hematopoiesis$106,158
R01 · FY2007 · CA · contact PI
T(8;21) in Blood Cell Proliferation and Differentiation$67,053
R01 · FY2007 · CA · contact PI
FASEB Conference-Hematological Malignancies$9,710
R13 · FY2007 · CA · contact PI
UBP43 in Hematopoiesis$387,657
R01 · FY2006 · CA · contact PI
Role of Ubiquitin Like Protein ISG15 Conjugation$333,847
R01 · FY2006 · GM · contact PI
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$131,733
R01 · FY2006 · CA · contact PI
T(8;21) in Blood Cell Proliferation and Differentiation$66,716
R01 · FY2006 · CA · contact PI
Role of Ubiquitin Like Protein ISG15 Conjugation$49,102
R01 · FY2006 · GM · contact PI
Mechanism of Interferon Response and Resistance in CML$274
R01 · FY2006 · CA · contact PI
Role of Ubiquitin Like Protein ISG15 Conjugation$403,555
R01 · FY2005 · GM
UBP43 in Hematopoiesis$396,986
R01 · FY2005 · CA
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$384,785
R01 · FY2005 · CA
T(8;21) in Blood Cell Proliferation and Differentiation$375,869
R01 · FY2005 · CA
Mechanism of Interferon Response and Resistance in CML$307,828
R01 · FY2005 · CA
Role of Ubiquitin Like Protein ISG15 Conjugation$403,555
R01 · FY2004 · GM
UBP43 in Hematopoiesis$396,986
R01 · FY2004 · CA
Molecular Mechanism of Leukemogenesis Involving AML1-ETO$384,785
R01 · FY2004 · CA
T(8;21) in Blood Cell Proliferation and Differentiation$375,869
R01 · FY2004 · CA
Mechanism of Interferon Response and Resistance in CML$307,828
R01 · FY2004 · CA
Ubiquitin Like Protein ISG15 Conjugation$403,555
R01 · FY2003 · GM
UBP43 in Hematopoiesis$396,986
R01 · FY2003 · CA
T(8;21) in Blood Cell Proliferation and Differentiation$375,869
R01 · FY2003 · CA
NOVEL DEUBIQUITINATING ENZYME, UBP46, IN HEMATOPOIESIS$46,300
R01 · FY2002 · CA
NOVEL DEUBIQUITINATING ENZYME, UBP46, IN HEMATOPOIESIS$320,620
R01 · FY2001 · CA
AML1 AND ITS FUSION PROTEINS IN HEMATOPOIESIS AND LEUKEMIA$279,549
P01 · FY2001 · CA
AML1 AND ITS FUSION PROTEINS IN HEMATOPOIESIS AND LEUKEMIA$348,824
P01 · FY2000 · CA
NOVEL DEUBIQUITINATING ENZYME, UBP46, IN HEMATOPOIESIS$311,280
R01 · FY2000 · CA